Advances in the diagnosis and management of lymphoma

References

• Sheehan WW, Rappaport H. Morphological criteria in the classification of the malignant lymphomas. Proc Natl Cancer Conf 1970;6:59–71.
   PubMedGoogle Scholar
• [No authors listed]. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982;49(10):2112–2135.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–1392.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Vose JM, Kantarjian H. Management of Hematologic Malignancies. Cambridge, UK: Cambridge University Press; 2011.
   Google Scholar
• World Health Organization/International Agency for Re search on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
   Google Scholar
• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 201161(4):212–236.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non- Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780–2795.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin’s lymphoma after infectious mononucleosis. N Engl J Med. 2003;349(14):1324–1332.
   PubMed Web of Science ®Google Scholar
• Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med. 1992;327(24):1710–1714.
   Web of Science ®Google Scholar
• Gunven P, Klein G, Henle G, Henle W, Clifford P. Epstein-Barr virus in Burkitt’s lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature. 1970;228(5276):1053–1056.
   Google Scholar
• Chua I, Quinti I, Grimbacher B. Lymphoma in common variable immunodeficiency: interplay between immune dysregulation, infection and genetics. Curr Opin Hematol. 2008;15(4):368–374.
   Web of Science ®Google Scholar
• Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338(8776):1175–1176.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seropreva- lence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100(1):107–115.
   PubMed Web of Science ®Google Scholar
• Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069–2077.
   PubMed Web of Science ®Google Scholar
• Hooper WC, Holman RC, Clarke MJ, Chorba TL. Trends in non- Hodgkin lymphoma (NHL) and HIV-associated NHL deaths in the United States. Am J Hematol. 2001;66(3):159–166.
   Web of Science ®Google Scholar
• Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS. 2000;14(12):1675–1688.
   Web of Science ®Google Scholar
• Cartwright R, McNally R, Staines A. The increasing incidence of non-Hodgkin’s lymphoma (NHL): the possible role of sunlight. Leuk Lymphoma. 1994;14(5–6):387–394.
   PubMed Web of Science ®Google Scholar
• Chiu BC, Weisenburger DD, Zahm SH, et al. Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2004;13(4):525–531.
   Web of Science ®Google Scholar
• Zahm SH, Weisenburger DD, Babbitt PA, Saal RC, Vaught JB, Blair A. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Am J Public Health. 1992;82(7):990–997.
   PubMed Web of Science ®Google Scholar
• Shugart YY, Hemminki K, Vaittinen P, Kingman A, Dong C. A genetic study of Hodgkin’s lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. Hum Genet. 2000;106(5):553–556.
   PubMed Web of Science ®Google Scholar
• Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;109(8):3479–3488.
   PubMed Web of Science ®Google Scholar
• Zhu K, Levine RS, Brann EA, et al. Risk factors for non-Hodgkin’s lymphoma according to family history of haematolymphoproliferative malignancies. Int J Epidemiol. 2001;30(4):818–824.
   Web of Science ®Google Scholar
• Altieri A, Bermejo JL, Hemminki K. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood. 2005;106(2):668–672.
   Web of Science ®Google Scholar
• Zelenetz AD, Hoppe RT. NCCN: Non-Hodgkin’s lymphoma. Cancer Control. 2001;8(6 Suppl 2):102–113.
   Google Scholar
• [No authors listed]. NCCN practice guidelines for Hodgkin’s disease. National Comprehensive Cancer Network. Oncology (Williston Park). 1999;13(5A):78–110.
   Web of Science ®Google Scholar
• Mourad WA, Tulbah A, Shoukri M, et al. Primary diagnosis and REAL/WHO classification of non-Hodgkin’s lymphoma by fine-needle aspiration: cytomorphologic and immunophenotypic approach. Diagn Cytopathol. 2003;28(4):191–195.
   Web of Science ®Google Scholar
• Young NA, Al-Saleem TI, Ehya H, Smith MR. Utilization of fine- needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. Cancer. 1998;84(4):252–261.
   Web of Science ®Google Scholar
• Matasar MJ, Shi W, Silberstien J, et al. Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Ann Oncol. 2012;23(1):159–166.
   Web of Science ®Google Scholar
• LaCasce AS, Kho ME, Friedberg JW, et al. Comparison of referring and final pathology for patients with non-Hodgkin’s lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008;26(31):5107–5112.
   PubMed Web of Science ®Google Scholar
• Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2009;20(3):508–512.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–1636.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• Gospodarowicz MK, Sutcliffe SB, Clark RM, et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin’s disease treated with radiation alone. Int JRadiat Oncol Biol Phys. 1992;22(5):859–865.
   Web of Science ®Google Scholar
• Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med. 1991;114(5):361–365.
   PubMed Web of Science ®Google Scholar
• Duhmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36(2):305–310.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479.
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472–2479.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102(6):1989–1996.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–26.
   PubMed Web of Science ®Google Scholar
• Hasenclever D. The disappearance of prognostic factors in Hodgkin’s disease. Ann Oncol. 2002;(13 Suppl 1):75–78.
   Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91(23):10962–10966.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Brousset P Knecht H, Rubin B, et al. Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin’s disease. Blood. 1993;82(3):872–876.
   Web of Science ®Google Scholar
• Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma. 2009;9(3):206–216.
   PubMedGoogle Scholar
• Klimm B, Franklin J, Stein H, et al. Lymphocyte-depleted classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2011;29(29):3914–3920.
   Web of Science ®Google Scholar
• Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993;71(6):2062–2071.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, et al. Pure infradiaphragmatic Hodgkin’s lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. Haematologica. 2006;91(1):32–39.
   Web of Science ®Google Scholar
• Kalkner KM, Enblad G, Gustavsson A, et al. Infradiaphragmatic Hodgkin’s disease: the Swedish National Care Programme experience. The Swedish Lymphoma Study Group. Eur J Haematol. 1997;59(1):31–37.
   Web of Science ®Google Scholar
• Ifrah N, Hunault M, Jais JP, et al. Infradiaphragmatic Hodgkin’s disease: long term results of combined modality therapy. Leuk Lymphoma. 1996;21(1–2):79–84.
   PubMed Web of Science ®Google Scholar
• Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin’s disease. Neurology. 1992;42(10):1938–1943.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Attardo-Parrinello G, Lattanzio G, Rizzo SC, Ascari E. Severe pruritus should be a B-symptom in Hodgkin’s disease. Cancer. 1983;51(10):1934–1936.
   Web of Science ®Google Scholar
• Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms in Hodgkin’s disease. Cancer. 1985;56(12):2874–2880.
   Web of Science ®Google Scholar
• Atkinson K, Austin DE, McElwain TJ, Peckham MJ. Alcohol pain in Hodgkin’s disease. Cancer. 1976;37(2):895–899.
   Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2- deoxy-D-glucose positron emission tomography is prognostic ally superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746–3752.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol. 2006;17(8):1296–1300.
   Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–59.
   PubMed Web of Science ®Google Scholar
• Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol. 2011;22(4):910–915.
   PubMed Web of Science ®Google Scholar
• Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol. 2001;19(22):4238–4244.
   Web of Science ®Google Scholar
• Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24(19):3128–3135.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634–4642.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacar- bazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483–3489.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431–3439.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252–259.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–1484.
   PubMed Web of Science ®Google Scholar
• Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11(11):2258–2272.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835–2841.
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–652.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Abramson JS, Fisher DC, LaCasce AS. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010;28(9):1611–1615.
   Web of Science ®Google Scholar
• Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630–637.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hong F, Fisher RI, et al. A randomized Phase III trial of ABVD vs Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin’s lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Blood. 2010;116: Abstr 415.
   Google Scholar
• Advani RH, Hong F, Fisher RI, et al. Randomized Phase III trial comparing ABVD + radiotherapy and the Stanford V regimen in patients with stage I/II bulky mediastinal Hodgkin lymphoma: a subset analysis of the US Intergroup trial E2496. Blood. 2010;116.
   Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased- dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348(24):2386–2395.
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1989;7(2):179–185.
   Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054.
   PubMed Web of Science ®Google Scholar
• Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood. 1994;83(5):1193–1199.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89(3):801–813.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–623.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol. 2004;124(5):645–652.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft- versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934–1941.
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35(10):943–951.
   Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821.
   PubMed Web of Science ®Google Scholar
• Regula DP Jr, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin’s disease. N Engl J Med. 1988;318(4):214–219.
   PubMed Web of Science ®Google Scholar
• Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin’s disease. N Engl J Med. 1997;337(7):459–465.
   Web of Science ®Google Scholar
• Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337(7):453–458.
   PubMed Web of Science ®Google Scholar
• Diehl V Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17(3):776–783.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006;24(3):146–150.
   Web of Science ®Google Scholar
• Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP. ASH Annual Meeting Abstracts. 2010;116(21):2812.
   Google Scholar
• Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109–111.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase II study of ritux- imab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011;118:4363–4365.
   PubMed Web of Science ®Google Scholar
• Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin’s disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma. 1997;26(3–4):359–368.
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991–9996.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68–74.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave S, et al. Gene expression signatures predict overall survival in diffuse large B cell lymphoma treated with ritux- imab and CHOP-like chemotherapy. ASH Annual Meeting Abstracts. 2007;110(11):348.
   Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828–1837.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836–4843.
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–207.
   PubMed Web of Science ®Google Scholar
• Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation – a population-based study of 1575 cases. Br J Haematology. 2004;124(2):151–159.
   PubMed Web of Science ®Google Scholar
• López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23(12):2797–2804.
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25(17):2426–2433.
   PubMed Web of Science ®Google Scholar
• Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13(7):1726–1733.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587–1594.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Chen TT, Levy R. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. J Exp Med. 1991;173(1):197–207.
   Web of Science ®Google Scholar
• Matolcsy A, Inghirami G, Knowles D. Molecular genetic demonstration of the diverse evolution of Richter’s syndrome chronic lymphocytic leukemia and subsequent large cell lymphoma. Blood. 1994;83(5):1363–1372.
   Web of Science ®Google Scholar
• Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol. 2002;13(7):1099–1107.
   PubMed Web of Science ®Google Scholar
• Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol. 2000;11(6):685–690.
   PubMed Web of Science ®Google Scholar
• Ryan GF, Roos DR, Seymour JF. Primary non-Hodgkin’s lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma. 2006;6(4):337–341.
   Google Scholar
• Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V Primary breast lymphoma. Leuk Lymphoma. 2003;44(7):1173–1178.
   PubMed Web of Science ®Google Scholar
• Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S. Non-Hodgkin lymphoma of the breast. Cancer. 2007;110(1):25–30.
   Web of Science ®Google Scholar
• Korfel A. Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how? Curr Opin Oncol. 2011;23(5):436–440.
   PubMed Web of Science ®Google Scholar
• McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484–1493.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–1006.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–4126.
   PubMed Web of Science ®Google Scholar
• Miller TP, Unger JM, Spier C, et al. Effect of adding rituximab to three cycles of CHOP plus invoved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). ASH Annual Meeting Abstracts. 2004;104(11):158.
   Google Scholar
• Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006;3(8):406–407.
   PubMedGoogle Scholar
• Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3 -weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–641.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03–6B GELA study. ASH Annual Meeting Abstracts. 2009;114(22):406.
   Google Scholar
• Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21: Result of a randomized Phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. ASCO Meeting Abstracts. 2011;29(15 Suppl):8000.
   Google Scholar
• Wilson WH. Drug resistance in diffuse large B-cell lymphoma. Semin Hematol. 2006;43(4):230–239.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose- adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717–2724.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–2331.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28(11):1896–1903.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336(18):1290–1297.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• van Kampen RJW, Canals C, Schouten HC, et al. Allogeneic stemcell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342–1348.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–3879.
   PubMed Web of Science ®Google Scholar
• Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163–208.
   PubMed Web of Science ®Google Scholar
• Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer. 1988;62(9):1893–1898.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130(5):691–699.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90(2):372–376.
   PubMed Web of Science ®Google Scholar
• van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001;19(6):1855–1864.
   Web of Science ®Google Scholar
• Moskowitz C, Hamlin PA Jr, Maragulia J, Meikle J, Zelenetz AD. Sequential dose-dense RCHOP followed by ICE vonsolidation (MSKCC protocol 01–142) without radiotherapy for patients with primary mediastinal large B cell lymphoma. ASH Annual Meeting Abstracts. 2010;116(21):420.
   Google Scholar
• Shenkier TN, Blay JY, O’Neill BP, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23(10):2233–2239.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510–522.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Blay J-Y, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group Experience. J Clin Oncol. 2003;21(2):266–272.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24(24):3865–3870.
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Ferreri AJ, Campo E, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007;25(21):3168–3173.
   PubMed Web of Science ®Google Scholar
• Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007;109(2):478–485.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Yri OE, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012;156(2):225–233.
   PubMed Web of Science ®Google Scholar
• Trotman J, Fournier M, Lamy T, et al. Positron emission tomography- computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194–3200.
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998;91(8):2955–2960.
   Web of Science ®Google Scholar
• Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001;51(5):1219–1227.
   PubMed Web of Science ®Google Scholar
• Richards MA, Gregory WM, Hall PA, et al. Management of localized non-Hodgkin’s lymphoma: the experience at St. Bartholomew’s Hospital 1972–1985. Hematol Oncol. 1989;7(1):1–18.
   Web of Science ®Google Scholar
• MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14(4):1282–1290.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16(7):2332–2338.
   Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311(23):1471–1475.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with Stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. ASH Annual Meeting Abstracts. 2010;116(21):6.
   Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meeting Abstracts. 2009;114(22):405.
   Google Scholar
• Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood. 2005;105(10):3817–3823.
   PubMed Web of Science ®Google Scholar
• Peters A, Russell JA, Daly A, et al. Autologous stem cell transplantation is a curative treatment modality for relapsed or refractory follicular lymphoma, and both recent rituximab exposure and follicular lymphoma international prognostic index (FLIPI) 0–1 scores predict improved outcome. ASH Annual Meeting Abstracts. 2010;116(21):687.
   Google Scholar
• Le Gouill S, De Guibert S, Planche L, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000study. Haematologica. 2011;96(8):1128–1135.
   PubMed Web of Science ®Google Scholar
• Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin- based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood. 2009;113(5):995–1001.
   PubMed Web of Science ®Google Scholar
• Toze CL, Barnett MJ, Connors JM, et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol. 2004;127(3):311–321.
   Web of Science ®Google Scholar
• van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102(10):3521–3529.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799–1806.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5):441–449.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19(19):3918–3928.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156–5164.
   PubMed Web of Science ®Google Scholar
• Piris MA, Arribas A, Mollejo M. Marginal zone lymphoma. Semin Diagn Pathol. 2011;28(2):135–145.
   Web of Science ®Google Scholar
• Pich A, Fraire F, Fornari A, et al. Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study. Eur J Haematol. 2006;76(5):392–398.
   Web of Science ®Google Scholar
• Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100(5):1648–1654.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005;105(1):74–76.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166(19):2101–2108.
   PubMedGoogle Scholar
• Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89–94.
   PubMed Web of Science ®Google Scholar
• Ohsawa M, Shingu N, Miwa H, et al. Risk of non-Hodgkin’s lymphoma in patients with hepatitis C virus infection. Int J Cancer. 1999;80(2):237–239.
   Web of Science ®Google Scholar
• Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120(5):759–764.
   PubMed Web of Science ®Google Scholar
• Bennett M, Schechter GP Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol. 2010;47(2):143–147.
   PubMed Web of Science ®Google Scholar
• Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23(31):8018–8024.
   PubMed Web of Science ®Google Scholar
• Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori- independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood. 2005;106(3):1037–1041.
   Web of Science ®Google Scholar
• Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;50(5):1258–1264.
   PubMed Web of Science ®Google Scholar
• Fung CY, Grossbard ML, Linggood RM, et al. Mucosa-associated lymphoid tissue lymphoma of the stomach: long term outcome after local treatment. Cancer. 1999;85(1):9–17.
   Web of Science ®Google Scholar
• Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747–758.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI. Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma. 2006;47(11):2365–2370.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.
   PubMed Web of Science ®Google Scholar
• Shanafelt T, Hanson CA. Monoclonal B-cell lymphocytosis: definitions and natural history. Leuk Lymphoma. 2009;50(3):493–497.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Bennett FL, O’Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575–583.
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Fischer K, Fink A-M, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood. 2011;117(6):1817–1821.
   Web of Science ®Google Scholar
• Gribben JG. How I treat CLL up front. Blood. 2010;115(2):187–197.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998;338(21):1506–1514.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmuno- therapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349–1355.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, et al. TP5 3 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473–4479.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27(24):3994–4001.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98(12):2657–2663.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(26):4378–4384.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559–3566.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749–1755.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118(19):5126–5129.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005;103(2):216–228.
   PubMed Web of Science ®Google Scholar
• Cohen PL, Kurtin PJ, Donovan KA, Hanson CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol. 1998;101(2):302–310.
   Web of Science ®Google Scholar
• Raty R, Franssila K, Jansson SE, Joensuu H, Wartiovaara-Kautto U, Elonen E. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. Eur J Cancer. 2003;39(3):321–329.
   Web of Science ®Google Scholar
• Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F- fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37(9):1633–1642.
   PubMed Web of Science ®Google Scholar
• Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol. 2010;21(1):133–139.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–1213.
   PubMed Web of Science ®Google Scholar
• Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96(8):1121–1127.
   PubMed Web of Science ®Google Scholar
• Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975–4981.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984–1992.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immuno-chemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687–2693.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus ritux- imab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(15):3383–3389.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867–4874.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822–3829.
   PubMed Web of Science ®Google Scholar
• Vose JM. Burkitt lymphoma. In: O’Brien S, Vose JM, Kantarjian HM, editors. Management of Hematologic Malignancies. Cambridge, UK: Cambridge University Press; 2011.
   Google Scholar
• Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23(19):4430–4438.
   PubMed Web of Science ®Google Scholar
• Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13(8):1264–1274.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17(8):2461–2470.
   Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100(7):1438–1448.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569–1580.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538–1543.
   PubMed Web of Science ®Google Scholar
• Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13(1):140–149.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–3408.
   PubMed Web of Science ®Google Scholar
• Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756–6767.
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284–4289.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–1189.
   PubMed Web of Science ®Google Scholar
• de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–4963.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• AbouYabis AN, Shenoy PJ, Flowers C, Lechowicz MJ. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis. ASH Annual Meeting Abstracts. 2007;110(11):3452.
   Google Scholar
• Vose JM; The International PTCL Project. International Peripheral T-Cell Lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. ASH Annual Meeting Abstracts. 2005;106(11):811.
   Google Scholar
• Rodriguez J, Conde E, Gutierrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007;79(1):32–38.
   PubMed Web of Science ®Google Scholar
• Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica. 2003;88(11):1272–1278.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(2):218–224.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1995;267(5196):316–317.
   PubMed Web of Science ®Google Scholar
• Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–2706.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913–3921.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):653–662.
   PubMed Web of Science ®Google Scholar